Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
Charlotte FeniouxChristophe LouvetEmilie ChartonFrancois RozetStanislas RopertDominique PrapotnichEric BarretRafael Sanchez-SalasAnnick MombetNathalie CathalaMarie-Liesse JouliaJean-Luc MolitorJulie HenriquesFranck BonnetainXavier CathelineauMostefa BennamounPublished in: BJU international (2018)
A steroid switch from P to D appears to be a safe and non-expensive way of obtaining long-term responses to AA in selected patients with mCRPC. A longer PFS has been observed in patients with previous long hormone sensitivity duration, and/or low PSA level and/or short time to PSA progression on AA+P.